research use only
Cat.No.S2615
| Related Targets | CXCR Hedgehog/Smoothened PKA AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas GPR |
|---|---|
| Other Adrenergic Receptor Inhibitors | ICI 118551 Hydrochloride (Zenidolol) L755507 Yohimbine HCl Atipamezole Higenamine hydrochloride Detomidine HCl Naftopidil Demethyl-Coclaurine Buflomedil HCl Fenoterol hydrobromide |
|
In vitro |
DMSO
: 67 mg/mL
(198.64 mM)
Water : 67 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 337.28 | Formula | C8H11NO3.C4H6O6.H2O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 108341-18-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Levophed | Smiles | C1=CC(=C(C=C1C(CN)O)O)O.C(C(C(=O)O)O)(C(=O)O)O.O | ||
| Targets/IC50/Ki |
alpha-adrenergic receptor
|
|---|---|
| In vitro |
Noradrenaline modulates the gain of evoked activity, especially in sensory areas. Noradrenaline promotes long-term synaptic plasticity, in addition to these data emphasizing its short-term influence. Noradrenaline would signal ‘gross changes in the environment that produce sensory information strongly violating top-down expectations’ and would, through an enhancement of ‘bottom-up’ information processing at the expense of irrelevant ‘top-down’ expectations, favor behavioral adjustment. Noradrenaline modulates drive and energy and exerts a fine regulation of specific processes including learning, memory, sleep, arousal and adaptation. Noradrenaline system is intimately involved in a range of psychological processes which, when disrupted, lead to the expression of classifiable psychiatric disorders. Noradrenaline appears to be involved in a range of psychological processes, including arousal (vigilance), cognition, learning and sleep regulation, and also in regulating response to stressors which might initiate or exacerbate depressive symptomatology. Noradrenaline deficiency in this pathway may reduce concentration, affect working memory and cause psychomotor retardation, resulting in apathy and depression,while an increase in noradrenaline in this pathway is predicted to alleviate poor concentration, apathy and depression. Noradrenaline effects are complex and depending on experimental conditions (ponto-medullary and medullary preparations) and species (rats or mice), exogenous Noradrenaline mainly facilitates or mainly inhibits the neonatal RRG, with a mixture of α1 facilitatory and α2 inhibitory effects.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06323512 | Not yet recruiting | Heart Failure |
Nanjing First Hospital Nanjing Medical University |
June 1 2024 | -- |
| NCT06068764 | Recruiting | Coronary Artery Disease |
Hartford Hospital |
December 5 2023 | Phase 4 |
| NCT06116305 | Not yet recruiting | Acute on Chronic Liver Failure |
Institute of Liver and Biliary Sciences India |
November 5 2023 | -- |
| NCT06013345 | Recruiting | Atrial Fibrillation |
Charles University Czech Republic |
October 25 2023 | Phase 3 |
| NCT05990933 | Not yet recruiting | Inflammatory Response|Diabetes type1|Hypoglycemia |
Cees Tack|Radboud University Medical Center |
September 2023 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.